ACRX Stock Summary and Trading Ideas (Acelrx Pharmaceuticals | NASDAQ:ACRX)

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States.

Acelrx Pharmaceuticals trades on the NASDAQ stock market under the symbol ACRX.

As of March 22, 2023, ACRX stock price climbed to $0.72 with 785,299 million shares trading.

ACRX has a beta of -0.29, meaning it tends to be less sensitive to market movements. ACRX has a correlation of 0.00 to the broad based SPY ETF.

ACRX has a market cap of $5.39 million. This is considered a Sub-Micro Cap stock.

Last quarter Acelrx Pharmaceuticals reported $507,000 in Revenue and -$.94 earnings per share. This fell short of revenue expectation by $-113,000 and exceeded earnings estimates by $.26.

In the last 3 years, ACRX stock traded as high as $58.80 and as low as $.57.

The top ETF exchange traded funds that ACRX belongs to (by Net Assets): VTI, VXF, ITOT.

ACRX has underperformed the market in the last year with a price return of -89.0% while the SPY ETF lost -11.3%. ACRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -68.2% and -38.1%, respectively, while the SPY returned +3.4% and -1.3%, respectively.

ACRX support price is $.62 and resistance is $.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRX stock will trade within this expected range on the day.